The Hoffman ALS Clinical Trial Awards Program
The Hoffman ALS Clinical Trial Awards fund early-stage, biomarker-driven ALS clinical trials to accelerate the development of new therapies and advance promising interventions toward FDA evaluation.
Funder: ALS Association
Due Dates (Anticipated): November 2026 (Letter of Intent) | February 2027 (Full proposal)
Funding Amounts: Up to $1,000,000 per award over 2–3 years, milestone-driven.
Summary: Supports early-stage, biomarker-driven ALS clinical trials (phase 1 or 2a) to accelerate therapy development and de-risk further drug development.
Description
The Hoffman ALS Clinical Trial Awards Program is designed to accelerate the development of new and improved therapies for amyotrophic lateral sclerosis (ALS) by funding early-stage clinical trials. The focus is on phase 1 or phase 2a, biomarker-driven trials that generate essential data on safety, dosing, and biomarkers, which are critical for advancing investigational therapies toward FDA evaluation. The program also supports trials of imaging tracers and encourages the testing of innovative or repurposed interventions, including small molecules, genetic therapies, stem cell approaches, peptides, antibodies, and antisense therapies. Projects may include participants with ALS, healthy subjects, and/or asymptomatic carriers.
